Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 7 Human study design for device testing.

Published byMilena Procházková Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 7 Human study design for device testing."— Presentation transcript:

1 Fig. 7 Human study design for device testing.
Human study design for device testing. Photographs of the three BP measurement devices for study: (A) the smartphone-based device, (B) a standard automatic arm cuff device (the reference device), and (C) a finger cuff device (a competing device). (D) Diagram of the experimental protocol for BP measurement using the devices shown in (A) to (C). The protocol included a learning phase for new users to become familiar with the smartphone-based device and a data collection phase involving a measurement with the reference device, two to four measurements with the smartphone-based device, 1 min of measurement with the finger cuff device, and a final measurement with the reference device. Study details are provided in the “Device testing: Formal human study” subsection of Materials and Methods. Anand Chandrasekhar et al., Sci Transl Med 2018;10:eaap8674 Published by AAAS

Download ppt "Fig. 7 Human study design for device testing."

Similar presentations

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.
First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.
Fig. 5. Performance of the MGA to enable or enhance locomotor control after SCI. Performance of the MGA to enable or enhance locomotor control after SCI.

Fig. 5. Performance of the MGA to enable or enhance locomotor control after SCI. Performance of the MGA to enable or enhance locomotor control after SCI.
Fig. 4. Biomechanical properties of treated tibiae.

Fig. 4. Biomechanical properties of treated tibiae.
Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 1 Crohn’s disease association within the LRRK2 locus.
Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.
Fig. 3. Frequencies of amino acids at critical PGT121 and 10-1074 contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.
Fig. 3. 3RMR response to graded ischemia ex vivo.

Fig. 3. 3RMR response to graded ischemia ex vivo.
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro
Increased ADMA in pregnancy is associated with SGA birth outcomes

Increased ADMA in pregnancy is associated with SGA birth outcomes
Fig. 5. Preliminary performance validation of the hydrogel in vivo in a rabbit model of scleral trauma. Preliminary performance validation of the hydrogel.

Fig. 5. Preliminary performance validation of the hydrogel in vivo in a rabbit model of scleral trauma. Preliminary performance validation of the hydrogel.

Similar presentations

Ads by Google